IO Biotech (NASDAQ: IOBT) announced topline results from its pivotal Phase 3 trial of Cylembio® plus KEYTRUDA® for first-line advanced melanoma treatment. While the combination showed clinical improvement in progression-free survival (19.4 months vs. 11.0 months), it narrowly missed statistical significance with HR=0.77 (p=0.056). Notable findings include a profound effect in PD-L1 …
Read More »IO Biotech Melanoma Drug Shows 19.4-Month PFS in Phase 3 Trial Despite Statistical Miss
